There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aurinia Pharmaceuticals (AUPH – Research Report), Merus (MRUS – Research Report) and Genfit SA (GNFT – Research Report) with bullish sentiments.
Aurinia Pharmaceuticals (AUPH)
In a report issued on September 19, Joseph Schwartz from SVB Securities reiterated a Buy rating on Aurinia Pharmaceuticals. The company’s shares closed last Tuesday at $7.62, close to its 52-week low of $6.28.
According to TipRanks.com, Schwartz is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Aurinia Pharmaceuticals is a Strong Buy with an average price target of $18.13, which is a 139.2% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $26.00 price target.
See the top stocks recommended by analysts >>
Merus (MRUS)
SVB Securities analyst Andrew Berens maintained a Buy rating on Merus yesterday. The company’s shares closed last Tuesday at $20.09.
According to TipRanks.com, Berens is a 3-star analyst with an average return of
Currently, the analyst consensus on Merus is a Strong Buy with an average price target of $41.60.
Genfit SA (GNFT)
SVB Securities analyst Thomas Smith reiterated a Buy rating on Genfit SA on September 19. The company’s shares closed last Tuesday at $4.15.
According to TipRanks.com, Smith is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Genfit SA has an analyst consensus of Moderate Buy, with a price target consensus of $8.00, implying a 91.4% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $8.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AUPH:
- SVB Securities Remains a Buy on Dice Therapeutics (DICE)
- Robert W. Baird Keeps Their Buy Rating on Thor Industries (THO)
- SVB Securities Reaffirms Their Buy Rating on Theravance Biopharma (TBPH)
- Bluebird Bio (BLUE) Receives a Hold from SVB Securities
- SVB Securities Reaffirms Their Hold Rating on Pfizer (PFE)